Free CE/CMEVideo

Mechanism of Action of 𝘒𝘙𝘈𝘚-Targeted Therapies

Release Date

September 28, 2026

Expiration Date

September 29, 2027

Credits

0.5 CME

Activity Overview

Over the past decade, oncology has begun to leverage a rapidly maturing effort to target the KRAS protein in RAS-altered cancers. This has led to the introduction of targeted therapies with the potential to offer unprecedented benefit to patients. Still, these agents differ greatly in their mechanisms of action, relevant alterations, and adverse event profiles.

In this module, David Hong explains the mechanisms of action of RAS/MAPK inhibitors approved or being investigated for patients with different forms of cancer, as well as how these agents fit into the paradigm of management of RAS-altered cancers.

Target Audience

This activity is directed toward medical oncologists, molecular pathologists, and other oncology health care professionals

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the role of KRAS/RAS mutations in solid tumors
Mechanism of Action of 𝘒𝘙𝘈𝘚-Targeted Therapies

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

Follow Us on Social Media!

You Also Might Like...

Course

Mechanism of Action of 𝘒𝘙𝘈𝘚-Targeted Therapies

Create Account